非酒精性脂肪性肝病相关慢加急性肝衰竭:一个不断增长且老龄化的队列,等待名单死亡率上升
该研究分析美国2005至2017年器官共享联合网络登记数据,评估非酒精性脂肪性肝病(NAFLD)相关慢加急性肝衰竭(ACLF)在肝移植候选者中的负担及等待名单结局。结果显示NAFLD-ACLF登记人数增幅最大(331.6%),且≥60岁患者中NAFLD-ACLF 1级等待名单死亡风险高于酒精相关肝病和丙型肝炎相关ACLF。
要点
- 2005至2017年NAFLD-ACLF等待名单登记人数从134增至574,增幅331.6%(P<0.001)。
- ≥60岁患者中,NAFLD-ACLF 1级等待名单死亡风险高于ALD-ACLF(SHR=1.24)和HCV-ACLF(SHR=1.35)。
- 2017年NAFLD-ACLF人群中≥60岁者占54.1%,且≥65岁比例显著上升(β=0.90;P=0.011)。
核心结论
- NAFLD是美国等待名单中与ACLF相关的肝硬化病因中增长最快的病因。
- 随着NAFLD人群持续增长和老龄化,NAFLD-ACLF患者可能有最高的等待名单死亡风险。
研究设计与样本
- 分析2005至2017年美国器官共享联合网络登记数据。
- 使用欧洲肝病学会/慢性肝衰竭标准识别ACLF患者,并分为NAFLD、酒精相关肝病(ALD)和丙型肝炎病毒(HCV)感染三类。
- 采用线性回归和Chow检验分析趋势,使用Fine和Gray竞争风险回归及Cox比例风险回归评估等待名单结局。
主要发现
- 2005至2017年,NAFLD-ACLF等待名单登记人数从134增至574,增幅331.6%(P<0.001),为研究人群中最大百分比增幅。
- ALD-ACLF登记人数从348增至1066,增幅206.3%(P<0.001);HCV-ACLF下降45.2%(P<0.001)。
- 截至2017年,NAFLD-ACLF人群主要为≥60岁者(54.1%),线性回归显示该组≥65岁患者比例显著上升(β=0.90;P=0.011)。
- 自2014年起,≥60岁患者中,NAFLD-ACLF 1级等待名单死亡风险高于ALD-ACLF(亚风险比[SHR]=1.24;95%置信区间[CI],1.05-1.44)和HCV-ACLF(SHR=1.35;95%CI,1.08-1.71)。
- ACLF 2级或3级患者中,三组死亡率相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We assessed the burden of nonalcoholic fatty liver disease (NAFLD)-related acute on chronic liver failure (ACLF) among transplant candidates in the United States, along with waitlist outcomes for this population. APPROACH AND RESULTS: We analyzed the United Network for Organ Sharing registry from 2005 to 2017. Patients with ACLF were identified using the European Association for the Study of the Liver/Chronic Liver Failure criteria and categorized into NAFLD, alcohol-associated liver disease (ALD), and hepatitis C virus (HCV) infection. We used linear regression and Chow's test to determine significance in trends and evaluated waitlist outcomes using Fine and Gray's competing risks regression and Cox proportional hazards regression. Between 2005 and 2017, waitlist registrants for NAFLD-ACLF rose by 331.6% from 134 to 574 candidates (P < 0.001), representing the largest percentage increase in the study population. ALD-ACLF also increased by 206.3% (348-1,066 registrants; P < 0.001), whereas HCV-ACLF declined by 45.2% (P < 0.001). As of 2017, the NAFLD-ACLF population consisted primarily of persons aged ≥60 years (54.1%), and linear regression demonstrated a significant rise in the proportion of patients aged ≥65 in this group (β = 0.90; P = 0.011). Since 2014, NAFLD-ACLF grade 1 was associated with a greater risk of waitlist mortality relative to ALD-ACLF (subhazard ratio [SHR] = 1.24; 95% confidence interval [CI], 1.05-1.44) and HCV-ACLF (SHR = 1.35; 95% CI, 1.08-1.71), among patients aged ≥60 years. Mortality was similar among the three groups for patients with ACLF grade 2 or 3. CONCLUSIONS: NAFLD is the fastest rising etiology of cirrhosis associated with ACLF among patients listed in the United States. As the NAFLD population continues to grow and age, patients with NAFLD-ACLF will likely have the highest risk of waitlist mortality.
引用
- Sundaram V, Jalan R, Shah P, et al. Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. Hepatology. 2021. PMID: 32961608. doi:10.1002/hep.31566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。